Sorry, this website is not ready for mobile preview. Make sure to check on Desktop for now.
About Us

Your Biologicals Journey Starts Here

A true partner from discovery to commercialization

60

years of AVS Bio partnership with developers and manufacturers of vaccines, therapeutics, diagnostics, and other human, animal, and environmental science breakthroughs.

We were the first to commercialize SPF egg production, and since then the company expanded its portfolio of products and services to include:

AVS Bio - Industries Diagnostics
Avian Antigens
Primary Cell Products
AVS Bio - Industries Vaccines
Testing Services
AVS Bio - USDA-licensed split manufacturing support (FFM)
USDA-Licensed Split Manufacturing Support (FFM)
Engineer antibodies and proteins
Antibodies and Proteins
Antibody discovery and development services
Antibody Discovery and Development Services

To ensure the highest quality, availability, and versatility of essential biological materials across the biopharma, animal health, and environmental science supply chains, AVS Bio continues to innovate for and alongside its customers with advanced materials discovery and development expertise.

Glass vials of avian biological products and chicken serum labeled for Avian Influenza, Marek’s Disease, and Infectious Bronchitis by AVS Bio, arranged in rows on a white background.
AVS Bio - Animals Chickens
hand holding egg in lab environment
AVS Bio Bottles

How we help you and your customers

To ensure the highest quality, availability, and versatility of essential biological materials across the biopharma and animal health supply chains, AVS Bio continues to innovate alongside its customers as they explore new approaches and require new biological materials at manufacturing scale.

Our History

1961

Originally founded as SPAFAS (Specific Pathogen Free Avian Supply), we started as an egg production and testing laboratory in Connecticut

1992

We were acquired by Charles River Laboratories and have since more than doubled our manufacturing capacity and laboratory footprint, cultivated relationships with customers and manufacturing partners around the world, and built new capabilities across diagnostic and bioprocessing applications.

1995

Laboratory and antiserum production expansion

1998

USDA licensed

2004

Founding ModiQuest as spin-off of Radboud UMC

2005

MQR: Founding of subsidiary ModiQuest Research (MQR) for internal R&D purposes

2007
  • UPE: Founding U-Protein Express (UPE) as spin-off of Utrecht University
  • UPE: Developed transient recombinant antibody production platform
2011

Establishment of MQR as CRO for antibody discovery via hybridoma and B cell selection and antibody production

2012

MQR moved from Radboud UMC Nijmegen to Pivot Park Oss

2013

MQR introduced phage display-based discovery services2014 MQR made ready-to-use Human and VHH phage libraries available

2015

MQR introduced cell line generation service and expanded in cell-based screening technologies

2016
  • MQR introduced antibody humanization and optimization technologies
  • Move of UPE from academic building to Life Science Incubator at the Utrecht Science Park to support expansion and throughput in recombinant protein and antibody production
2017
  • UPE acquired by ImmunoPrecise Antibodies
  • MQR expanded high throughput production and screening capabilities
2018

MQR acquired by ImmunoPrecise Antibodies and rebranded to ImmunoPrecise Antibodies (Europe) B.V.

2019

IPA-EU expanded in genetic immunization services and launched DeepDisplay

2020

IPA-EU acquired the CellCelector to expand B cell-based discovery

2021
  • Merger of UPE with ImmunoPrecise Antibodies (Europe) B.V. (IPA-EU)
  • IPA-EU merged with UPE, Oss launched high throughput in vitro developability profiling platform and rabbit antibody humanization technology
2022
  • After 30 years of operating as a subsidiary of Charles River Laboratories, AVS reestablished itself as an independent company to begin a new chapter of accelerated investment across the Immunology landscape
  • IPA-EU: Expansion of functional screening services in Oss
2023

Oss launched chicken antibody humanization technology and B cell-based VHH discovery, Utrecht launched high throughput bispecific production and purification platform

2024

Move of Oss site to Curie Building, Oss launched Multiparametric humanization technology and acquired the LSA to expand SPR-based analytics

2025
  • Oss implemented the xCelligence to expand functional screening capabilities
  • August, 2025 ImmunoPrecise Antibodies (Europe) acquired by AVS Bio